PRTC Stock - PureTech Health plc
Unlock GoAI Insights for PRTC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $4.83M | $3.33M | $2.09M | $9.98M | $8.34M |
| Gross Profit | $1.26M | $-1,603,000 | $-136,815,000 | $-100,492,000 | $8.34M |
| Gross Margin | 26.0% | -48.1% | -6546.2% | -1007.0% | 100.0% |
| Operating Income | $-136,095,000 | $-146,199,000 | $-197,807,000 | $-150,282,000 | $-119,531,000 |
| Net Income | $53.51M | $-65,697,000 | $-50,355,000 | $-60,558,000 | $5.99M |
| Net Margin | 1108.3% | -1972.9% | -2409.3% | -606.9% | 71.8% |
| EPS | $2.00 | $-2.40 | $-1.80 | $-2.10 | $0.20 |
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 9th 2024 | Leerink Partners | Resumed | Outperform | $45← $58 |
Earnings History & Surprises
PRTCEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 28, 2026 | — | — | — | — |
Q3 2025 | Aug 28, 2025 | $-2.04 | $-1.86 | +8.9% | ✓ BEAT |
Q2 2025 | Apr 30, 2025 | $-2.83 | $0.35 | +112.5% | ✓ BEAT |
Q3 2024 | Aug 28, 2024 | $-3.03 | $-0.15 | +94.9% | ✓ BEAT |
Q2 2024 | Apr 25, 2024 | $-3.25 | $-0.15 | +95.5% | ✓ BEAT |
Q2 2023 | Apr 28, 2023 | $0.34 | $-0.08 | -124.1% | ✗ MISS |
Q3 2022 | Aug 25, 2022 | $-2.75 | $-0.10 | +96.4% | ✓ BEAT |
Q2 2022 | Apr 21, 2022 | $-2.45 | $0.05 | +102.1% | ✓ BEAT |
Q3 2021 | Aug 24, 2021 | $-2.31 | $-0.26 | +88.6% | ✓ BEAT |
Q2 2021 | Apr 15, 2021 | $-2.00 | $-0.41 | +79.8% | ✓ BEAT |
Q2 2020 | Jun 30, 2020 | — | $0.42 | — | — |
Q4 2019 | Dec 31, 2019 | — | $1.34 | — | — |
Q2 2019 | Jun 30, 2019 | — | $0.10 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-0.13 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.03 | — | — |
Q4 2017 | Dec 31, 2017 | — | $0.28 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-0.18 | — | — |
Q4 2016 | Dec 31, 2016 | — | $-0.08 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-0.13 | — | — |
Q4 2015 | Dec 31, 2015 | — | $-0.13 | — | — |
Latest News
PureTech Names Interim CEO Robert Lyne As Chief Executive Officer
➖ NeutralPureTech Confirms Phase 3 SURPASS-IPF For Deupirfenidone (LYT-100) On Track For H1 2026 After FDA End-Of-Phase 2 Meeting
➖ NeutralPureTech Health Announces Initial Topline Results From Phase 1b Clinical Trial Evaluating LYT-200, Anti-Galectin-9 Monoclonal Antibody, In Patients With r/r AML And High-Risk MDS
➖ NeutralPureTech Health To Share New Data From Ongoing Phase 1b Clinical Trial Evaluating LYT-200, Anti-Galectin-9 Monoclonal Antibody, In r/rAML At ASH 2025
➖ NeutralPureTech Highlights Deupirfenidone's Ability To Stabilize Lung Function While Maintaining Strong Tolerability In Older Adults With Idiopathic Pulmonary Fibrosis At CHEST 2025 Annual Meeting
📈 PositivePureTech Presents Phase 2b Open-Label Extension Data Showing Deupirfenidone Stabilizes Lung Function In IPF With Favorable Tolerability
📈 PositivePuretech Founded Entity Seaport Therapeutics Doses First Participant In Phase 1 Study Of Glyphago SPT-320 Oral Prodrug Of Agomelatine For Generalized Anxiety Disorder
📈 PositivePureTech Health Cash Runway Extended
📈 PositivePureTech Health H1 EPS $(0.19) Down From $(0.15) YoY, Sales $1.85M Up From $288.00K YoY
➖ NeutralPureTech Health Showcases Phase 2b Data At IPF Summit, Launches Celea Therapeutics To Advance Deupirfenidone Toward Phase 3
📈 PositiveFrequently Asked Questions about PRTC
What is PRTC's current stock price?
What is the analyst price target for PRTC?
What sector is PureTech Health plc in?
What is PRTC's market cap?
Does PRTC pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to PRTC for comparison